The emergence of cell therapies—particularly those derived from induced pluripotent stem cells (iPSCs)—represents one of the most transformative advances in modern medicine. Nowhere is this more evident than in neurology, where diseases such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and amyotrophic lateral sclerosis remain largely refractory to disease-modifying interventions. My vision centers on moving beyond proof-of-concept efficacy toward a durable, scalable framework that ensures these therapies are not confined to a narrow subset of patients, but instead become broadly accessible, affordable, and deliverable at or near the point of care.
At present, the field faces a paradox: scientific progress is accelerating, yet access remains constrained. Manufacturing complexity, regulatory fragmentation, high per-patient costs, and limited clinical infrastructure collectively threaten to transform curative therapies into boutique interventions. To avoid this outcome, a deliberate strategy is required—one that integrates manufacturing innovation, clinical delivery redesign, and new economic models.
Access: From Centers of Excellence to Distributed Networks
Historically, advanced therapies have been delivered through a small number of academic medical centers. While this model ensures quality and oversight, it inherently limits access. Patients with neurodegenerative diseases often face mobility challenges, making repeated travel to specialized centers impractical. A democratized model must therefore transition from centralized “centers of excellence” to a distributed network of qualified treatment sites.
This transition requires standardization at multiple levels: surgical procedures, cell handling protocols, imaging-guided delivery techniques, and post-treatment monitoring. Technologies such as robotic stereotactic systems, cloud-based imaging analytics, and digital twins derived from MRI and diffusion tensor imaging can help normalize outcomes across sites. Importantly, training programs must expand beyond elite neurosurgical teams to include regional specialists, supported by tele-mentoring and real-time procedural guidance.
The U.S. healthcare system, despite its fragmentation, provides a unique testing ground for such distributed models. Integrated delivery networks, Veterans Affairs hospitals, and large multi-state health systems could serve as early adopters. Once validated, this framework can be adapted internationally, particularly in countries with centralized healthcare infrastructures where rapid scaling may be more feasible.
Affordability: Reengineering the Cost Structure
Cell therapies today are among the most expensive interventions in medicine, often exceeding several hundred thousand dollars per patient. These costs are driven by bespoke manufacturing processes, stringent quality control requirements, and logistical complexities. If neurological cell therapies are to achieve widespread adoption, their cost structure must be fundamentally reengineered.
One pathway is the transition from autologous to allogeneic cell sources. Allogeneic iPSC-derived cells enable batch manufacturing, economies of scale, and inventory-based distribution, reducing per-dose costs. However, this approach must be paired with advances in immunoengineering—such as HLA matching, gene editing to reduce immunogenicity, or transient immunosuppression protocols—to ensure durability of engraftment.
Equally important is the development of value-based payment models. Traditional fee-for-service reimbursement is ill-suited for therapies with high upfront costs and long-term benefits. Outcomes-based contracts, annuity payments, and risk-sharing agreements between manufacturers, payers, and providers can align incentives while mitigating financial barriers to adoption. In the U.S., public payers such as Medicare and Medicaid will play a critical role in setting precedents for coverage.
Internationally, affordability challenges may be even more pronounced. Here, tiered pricing strategies, public-private partnerships, and local manufacturing capabilities can help bridge the gap. The goal is not merely to export therapies, but to enable their sustainable integration into diverse healthcare systems.
Point-of-Care Manufacturing: The Next Frontier
Perhaps the most transformative element of my vision is the shift toward point-of-care or near-point-of-care (POC) manufacturing. Traditional centralized manufacturing facilities, while efficient at scale, introduce delays, logistical risks, and high distribution costs. For neurological diseases—where timing, viability, and precision are critical—these limitations are particularly acute.
Advances in modular, closed-system bioreactors and automated cell processing platforms now make it conceivable to produce clinical-grade cell therapies within hospitals or POC-surgical hybrid ambulatory settings. These systems can standardize production, reduce contamination risk, and enable real-time quality control. When coupled with digital manufacturing records and regulatory-compliant data systems, point-of-care production can meet stringent safety and efficacy standards.
In the United States, regulatory frameworks will need to evolve to accommodate this paradigm. The U.S. Food and Drug Administration has already begun exploring decentralized manufacturing models, but further clarity is needed regarding site certification, batch release criteria, and oversight responsibilities. A hub-and-spoke model—where centralized facilities provide master cell banks and oversight, while regional centers perform final differentiation and formulation—may offer a pragmatic path forward.
Globally, point-of-care manufacturing holds even greater promise. In regions with limited infrastructure, the ability to produce therapies locally could bypass many of the barriers associated with importation and cold-chain logistics. However, this will require investment in workforce training, quality systems, and regulatory harmonization.
Integration: A Systems-Level Approach
Democratizing cell therapy is not a single innovation but a systems-level transformation. It requires alignment across scientific, clinical, regulatory, and economic domains. Data integration will be critical: real-world evidence collected across distributed sites can inform continuous improvement, refine patient selection, and support regulatory decision-making.
Artificial intelligence and machine learning can further enhance this ecosystem, enabling predictive modeling of treatment outcomes, optimization of manufacturing processes, and early detection of adverse events. Importantly, these tools must be deployed with transparency and equity in mind, ensuring that they do not inadvertently exacerbate existing disparities.
Conclusion: From Innovation to Equity
The promise of cell therapy for neurological disease is profound, offering the potential not only to alleviate symptoms but to modify—or even reverse—the course of disease. Yet without deliberate action, this promise risks being realized only for a privileged few. The advanced herein challenges the field to think beyond innovation toward equity: to design systems that are as scalable as they are effective, as affordable as they are advanced.
By expanding access through distributed care networks, reducing costs through manufacturing innovation and new payment models, and embracing point-of-care production, it is possible to create a future in which cell therapies are not exceptional interventions, but standard-of-care treatments available to all who need them. The United States can lead this transformation, but its ultimate success will be measured by its global impact—by how effectively these therapies are translated, adapted, and delivered across diverse healthcare systems worldwide.